Velpatasvir is a highly potent, pan‑genotypic HCV NS5A inhibitor that blocks viral assembly and replication. It is almost exclusively used in fixed‑dose combination with sofosbuvir to achieve high cure rates across all hepatitis C virus genotypes.
Approved Indications
Chronic hepatitis C (HCV) infection in adults
Used with sofosbuvir for genotypes 1, 2, 3, 4, 5, 6
Used with or without ribavirin depending on cirrhosis status
Key Features
Pan‑genotypic activity against HCV 1–6
High potency and high barrier to resistance
Oral once‑daily dosing
Cornerstone of single‑tablet regimen (STR) for HCV
Applications
API, intermediates, reference standards for R&D, generic registration and commercial manufacturing.
ECROBOT CO., Ltd, Business Registration Number : 220-88-71747, CEO J.W.Park, TEL : +82-2-552-7676, E-mail : E-mail : Contact us Address : (Hwanghwa B/D 11F, Yeoksam-dong)320, Gangnam-daero, Gangnam-gu, Seoul, South Korea
China [CN] 
Click enlarge Image